To read the full article sign up for free or sign in.

Moderna tops public biopharma raises with $1.34B to help fund its COVID-19 vaccine

May 19, 2020

Representing the highest amount ever raised by a public biopharma company on a U.S. exchange, Moderna Inc. priced a $1.34 billion follow-on offering to help fund worldwide manufacturing and distribution of its mRNA-1273 vaccine for COVID-19.

BioWorld Financings Coronavirus Vaccine Follow-on

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

H5N8 avian flu emerges as next public health concern

BioWorld

In their latest submission to Science, Weifeng Shi, director and professor at the Institute of Pathogen Biology at Shandong First Medical University in China, and...

Pfizer vaccine less effective against India variant of SARS-CoV-2

BioWorld

LONDON – A new U.K. study indicates the Pfizer Inc./Biontech SE COVID-19 vaccine is less effective against the India variant of the SARS-CoV-2 virus that was...

Novo to launch weekly weight loss drug Wegovy at same price as daily shot

BioWorld

Novo Nordisk A/S will this month launch its weekly weight loss glucagon-like peptide-1 injection Wegovy (semaglutide) at the same monthly cost as its older daily...

H5N8 avian flu emerges as next public health concern

BioWorld Asia

In their latest submission to Science, Weifeng Shi, director and professor at the Institute of Pathogen Biology at Shandong First Medical University in China, and...